Current Use of Pegasys for Hepatitis C
Pegasys (peginterferon alfa-2a) is no longer a standard treatment for hepatitis C. Direct-acting antivirals (DAAs) like sofosbuvir and glecaprevir/pibrentasvir, approved since 2014, cure over 95% of cases with 8-12 week oral regimens and fewer side effects. Guidelines from AASLD/IDSA (updated 2023) recommend DAAs as first-line, listing interferon-based therapies like Pegasys only for rare cases, such as DAA failures in specific genotypes or resource-limited settings.[1][2]
Pegasys Role in Hepatitis B Treatment
Pegasys remains approved and used for chronic hepatitis B (CHB), particularly HBeAg-positive or -negative adults. It boosts immune response to suppress HBV DNA and promote seroconversion. EASL (2022) and AASLD (2018) guidelines position it as an option alongside nucleos(t)ide analogs like entecavir, especially when finite therapy is preferred over lifelong treatment.[3][4]
Why the Shift from Hepatitis C?
Interferons like Pegasys caused flu-like symptoms, depression, and anemia in up to 80% of patients, with cure rates under 50% even combined with ribavirin. DAAs eliminated this need by 2016 in high-income countries, though Pegasys lingers in some low-resource areas due to cost (DAAs ~$25,000/course vs. generics ~$500).[5]
Availability and Patent Status
Roche markets Pegasys in vials for subcutaneous injection. U.S. patents expired around 2020-2025 for key formulations, allowing generics in some markets; check DrugPatentWatch.com for expiry details by country.[6]
Sources
[1]: AASLD/IDSA HCV Guidance (2023)
[2]: FDA DAA Approvals
[3]: EASL HBV Guidelines (2022)
[4]: AASLD HBV Guidance (2018)
[5]: WHO Hepatitis Strategy
[6]: DrugPatentWatch.com - Pegasys